Pharmacology of Drug Resistance

  • G. L. Drusano
Part of the Infectious Disease book series (ID)

Resistance of pathogens to antimicrobial agents is a major problem for all fi elds of anti-infective therapy. Certainly, we are in a crisis of resistance with respect to antibacterial agents (1). Therapy of human immunodefi ciency virus (HIV) is often restricted by multidrug resistance (2). Multidrugresistant TB is exploding in several areas of the world. Most of the discussion below will focus on bacteria, but the ideas are applicable to any pathogen.


Minimum Inhibitory Concentration Antimicrob Agent Infection Model Resistance Determinant Bacillus Anthracis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Talbot, GH, J Bradley, JE Edwards, Jr, D Gilbert, M Scheld, JG Bartlett. Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657–658PubMedCrossRefGoogle Scholar
  2. 2.
    Little, SJ, S Holte, JP Routy, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385–394PubMedCrossRefGoogle Scholar
  3. 3.
    Vogelman, B, S Gudmundsson, J Leggett, J Turnidge, S Ebert, WA Craig. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988;158:831–847PubMedGoogle Scholar
  4. 4.
    Craig, WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1–12PubMedCrossRefGoogle Scholar
  5. 5.
    Craig, WA. Interrelationship between pharmacokinetics and phar-macodynamics in determining dosing regimens for broad spectrum cephalosporins. Diagn Micro Infect Dis 1995;22:89–96CrossRefGoogle Scholar
  6. 6.
    Drusano, GL, DE Johnson, M Rosen, and HC Standiford. Pharmacodynamics of a fluoroquinolone antimicrobial in a neu-tropenic rat model of Pseudomonas sepsis. Antimicrob Agents Chemother 1993;37:483–490PubMedGoogle Scholar
  7. 7.
    Andes, D, WA Craig. Pharmacodynamics of the new fluoroqui-nolone gatifloxacin in murine thigh and lung infection models. Antimicrob Agents Chemother 2002;46:1665–1670PubMedCrossRefGoogle Scholar
  8. 8.
    Merriken, DJ, J Briant, GN Rolinson. Effect of protein binding on antibiotic activity in vivo. J Antimicrob Chemother 1983;11:233–238CrossRefGoogle Scholar
  9. 9.
    Preston, SL, GL Drusano, AL Berman, CL Fowler, AT Chow, B Dornseif, V Reichl, J Natarajan, FA Wong, M Corrado. Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrob Agents Chemother 1998;42:1098–1104PubMedGoogle Scholar
  10. 10.
    Drusano, GL, SL Preston, C Hardalo, R Hare, C Banfield, O Vesga, D Andes and WA Craig. Use of preclinical data for the choice of a Phase II/III dose for evernimicin with application to decision support for identification of a preclinical MIC breakpoint. Antimicrob Agents Chemother 2001;45:13–22PubMedCrossRefGoogle Scholar
  11. 11.
    Lodise, TP, B Lomaestro, KA Rodvold, LH Danziger, GL Drusano. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharma-cokinetic models and Monte Carlo simulation. Antimicrob Agents Chemother 2004;48:4718–4724PubMedCrossRefGoogle Scholar
  12. 12.
    Jumbe, NL, A Louie, MH Miller, W Liu, MR Deziel, VH Tam, R Bachhawat, GL Drusano. Quinolone efflux pumps play a central role in emergence of resistance to fluoroquinolones in Streptococcus pneumoniae. Antimicrob Agents Chemother 2006;50:310–317PubMedCrossRefGoogle Scholar
  13. 13.
    Tam, VH, A Louie, MR Deziel, W Liu, R Leary, GL Drusano. Bacterial population responses to drug selective pressure: examination of garenoxacin against Pseudomonas aeruginosa. J Infect Dis. 2005;192:420–428PubMedCrossRefGoogle Scholar
  14. 14.
    Jumbe, N, A Louie, R Leary, W Liu, MR Deziel, VH Tam, R Bachhawat, C Freeman, JB Kahn, K Bush, M N Dudley, MH Miller, GL Drusano. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest 2003;112:275–285PubMedGoogle Scholar
  15. 15.
    Deziel, M, H Heine, A Louie, M Kao, WR Byrne, J Bassett, L Miller, K Bush, M Kelley, GL Drusano. Identification of effective antimicrobial regimens for use in humans for the therapy of Bacillus anthracis infections and post-exposure prophylaxis. Antimicrob Agents Chemother 2005;49:5099–5106PubMedCrossRefGoogle Scholar
  16. 16.
    Peloquin, CA, TJ Cumbo, DE Nix, MF Sands, JJ Schentag. Evaluation of intravenous ciprofloxacin in patients with nosoco-mial lower respiratory tract infections: impact of plasma concentration and clinical condition on bacterial eradication. Arch Intern Med 1989;149:2269–2273PubMedCrossRefGoogle Scholar
  17. 17.
    Fink, MS, DR Snydman, MS Niederman, KV Leeper, Jr, RH Johnson, SO Heard, RG Wunderink, JW Caldwell, JJ Schentag, GA Siami, et al. Treatment of severe pneumonia in hospitalized patients: results of a randomized, double-blind trial comparing intravenous ciprofloxacin with imipenem-cilastatin. Antimicrob Agents Chemother 1994;38:547–557PubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2009

Authors and Affiliations

  • G. L. Drusano
    • 1
  1. 1.Ordway Research InstituteAlbanyUSA

Personalised recommendations